The first-patient-dosed milestone de-risks GB-5267's clinical entry but provides no efficacy signal. Watch for initial safety/tolerability data from the Phase 1 trial, which could take 12-18 months. The AI-designed CAR T approach is novel but unproven in humans.
Price Chart
Executive Summary
Generate Biomedicines announced the first patient dosed in a Phase 1 trial of GB-5267, an AI-designed IL-18 armored CAR T-cell therapy for platinum-resistant ovarian cancer. This is an early clinical milestone with no efficacy or safety data yet, representing a modest positive catalyst for the company's pipeline.
Key Facts
- First patient dosed in Phase 1 trial (NCT07489287) evaluating GB-5267, an autologous IL-18 armored CAR T-cell therapy targeting MUC16
- Trial is for platinum-resistant ovarian cancer, a difficult-to-treat indication with 51.6% five-year survival rate
- GB-5267 was engineered using AI to optimize potency, proliferation, and persistence in solid tumors
- Treatment is designed to avoid pre-infusion chemotherapy (lymphodepletion), potentially reducing side effects
- Trial is led by Roswell Park Comprehensive Cancer Center, with Principal Investigator Emese Zsiros
Financial Impact
No financial terms disclosed; early-stage clinical trial with no revenue impact
Risk Factors
- Phase 1 trial is early-stage with high failure rate for novel CAR T therapies in solid tumors
- No clinical data yet; safety and efficacy remain unproven
- Ovarian cancer is a competitive space with multiple CAR T and bispecific approaches in development
- Company is clinical-stage with no approved products, dependent on capital markets for funding
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $12.52 | awaiting T+20 | — | $13.21 (+5.51%) |
Oct 1, 2026 26d ago | Press Release | $13.80 | awaiting T+20 | — | $13.21 (−4.28%) |
May 7, 2026 24w ago | 8-K | $13.59 $12.91 | ▲ +5.00% | ▲ +8.14% | $13.21 (+2.80%) |
Mar 2, 2026 34w ago | Insider Cluster | $11.93 $12.50 | ▲ +4.78% | ▲ +9.19% | $13.21 (+10.73%) |
Mar 2, 2026 34w ago | Insider Cluster | $11.93 $12.50 | ▲ +4.78% | ▲ +9.19% | $13.21 (+10.73%) |
Feb 27, 2026 34w ago | 424B4 | $12.17 $11.51 | ▲ +5.42% | ▼ −2.52% | $13.21 (−8.55%) |
Feb 27, 2026 34w ago | EFFECT | $12.65 $11.44 | ▼ −9.57% | ▼ −2.01% | $13.21 (+4.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers